Mismatch repair protein immunohistochemistry is a widely used method for detecting patients at risk for Lynch syndrome. Recent data suggest that a two-antibody panel approach using PMS2 and MSH6 is an effective screening protocol for colorectal carcinoma, but there are limited data concerning this approach for extraintestinal tumors. The purpose of this study was to review the utility of a two-antibody panel approach in colorectal carcinoma and extraintestinal tumors. We evaluated mismatch repair protein expression in two cohorts: (1) a retrospective analysis of intestinal and extraintestinal tumors (n ¼ 334) tested for mismatch repair protein immunohistochemistry and (2) Skin sebaceous neoplasms more frequently demonstrated abnormal expression of MSH6 (18/24, 75%, respectively). A total of 65 tumors with abnormal mismatch repair protein expression were tested for microsatellite instability (MSI): 47 (72%) MSI high, 9 (14%) MSI low, and 9 (14%) microsatellite stable (MSS). Abnormal MSH6 expression accounted for 14/18 (78%) cases that were MSS or MSI low. Our findings confirm the utility of a two-antibody approach using PMS2 and MSH6 in colorectal carcinoma and indicate that this approach is effective in extraintestinal neoplasms associated with Lynch syndrome.
In the mid-1960s, Henry Lynch described a family from Nebraska with an unusually high prevalence of early colorectal carcinoma characterized by an absence of polyposis, 1 now known as hereditary nonpolyposis colorectal cancer or Lynch syndrome. Currently, Lynch syndrome is the most commonly diagnosed form of hereditary colorectal carcinoma accounting for 3-5% of all colorectal carcinomas. Germline mutations in four DNA mismatch repair genes are thought to give rise to Lynch syndrome: MLH1 (40-45% of cases), MSH2 (40-45%), MSH6 (5-10%), and PMS2 (o5%). [2] [3] [4] [5] [6] [7] [8] [9] Currently, in B5% of cases a germline mutation in a known DNA mismatch repair gene cannot be identified. 1 Affected persons with Lynch syndrome are at risk for neoplasia in the colon but also have an elevated risk of developing tumors of the endometrium, ovary, skin, stomach, biliary tract, and upper urinary tract. syndrome who present with extraintestinal disease. In women with Lynch syndrome, the incidence of endometrial carcinoma equals or exceeds that of colorectal carcinoma, 10, 11 and the lifetime risk for endometrial carcinoma in Lynch syndrome is between 40 and 60% compared with 3% for the general population. 11 Identifying patients at risk for Lynch syndrome requires evaluation of endometrial carcinoma for mismatch repair protein abnormalities, and is important as these patients are at risk for synchronous or metachronous Lynch syndromerelated tumors 10 and would benefit from close surveillance and genetic counseling. 12 Muir-Torre syndrome (MTS) is a clinical variant of Lynch syndrome, and MTS patients typically present with a cutaneous sebaceous neoplasm and have at least one visceral malignancy. 13 Increasingly, patients with multiple sebaceous neoplasms or family history concerning MTS are being screened for mismatch repair protein abnormalities. [14] [15] [16] [17] [18] Recent literature has shown that in these patients, mismatch repair protein immunohistochemistry is a useful screening tool. 19 Historically, microsatellite instability (MSI) testing was considered superior to mismatch repair protein immunohistochemistry in identifying patients with Lynch syndrome. 7 This was primarily because of the limitations of MLH1 immunohistochemistry. The sensitivity of MLH1 immunohistochemistry for detecting germline MLH1 mutations is only B74% compared with 490% sensitivity for MSI. 7 A small subset of MLH1 truncating and nontruncating mutations results in antigenically active functionally inactive protein, leading to spurious results with MLH1 immunohistochemistry. [20] [21] [22] Because of the low sensitivity of MLH1 immunohistochemistry alone, PMS2 has been added to the mismatch repair protein immunohistochemistry panel. 22 Recent literature suggests that the use of all four antibodies (MLH1, MSH2, MSH6, and PMS2) is as sensitive in predicting germline mismatch repair protein mutations as MSI testing. [23] [24] [25] The addition of MSH6 immunohistochemistry also adds sensitivity, as MSH6 germline mutations often yield only low levels of MSI that may not be detected with the microsatellites tested by PCR analysis. 26, 27 In their functional state within a cell, MLH1 dimerizes with PMS2 and MSH2 dimerizes with MSH6. 22, 24, [28] [29] [30] MLH1 and MSH2 are the obligatory partners for their respective heterodimers. In general, germline mutations in the obligatory partners MLH1 and MSH2 most often will result in degradation of the heterodimer and the consequent proteolytic degradation of their respective secondary partners, PMS2 and MSH6. 29 In contrast, germline mutations in the secondary partners MSH6 and PMS2 may not result in proteolytic degradation of its obligatory partner, as the function of the secondary protein may be compensated by other proteins. Based on this concept, a two-antibody panel of PMS2 and MSH6 for screening colorectal carcinoma by mismatch repair protein immunohistochemistry has been proposed. 31 In their study, Shia et al 31 reviewed 232 cases of colorectal carcinoma and demonstrated no isolated loss of MLH1 or isolated loss of MSH2, suggesting that a two-antibody screen including MSH6 and PMS2 is efficacious for colorectal carcinoma, potentially reducing the cost of mismatch repair protein immunohistochemistry. Similarly, Hall et al 32 confirmed these findings in their analysis of 344 cases of colorectal carcinoma. However, the utility of the two-antibody panel has not been well studied in extraintestinal Lynch syndrome-related tumors. Herein, we report the findings of our examination of mismatch repair protein immunohistochemistry to determine the utility of the two-antibody mismatch repair protein immunohistochemistry screening approach in intestinal and extraintestinal tumors with particular attention to gynecologic tract and sebaceous tumors.
Materials and methods

Study Groups
We analyzed two groups of patients who had testing for mismatch repair protein immunohistochemistry with or without concurrent MSI testing. The first group consisted of a retrospective analysis of all intestinal and extraintestinal tumors tested for mismatch repair protein immunohistochemistry within the archives of the Department of Pathology at Stanford University Medical Center from January 2003 through April 2010. The cases were selected for analysis based on at least one of the following: (1) age o50 years, (2) clinical concern for Lynch syndrome meeting requirements of the Bethesda criteria (ie, patient with synchronous or metachronous colorectal carcinoma or other Lynch syndromeassociated tumor regardless of age; colorectal carcinoma diagnosed in one or more first-degree relatives with a Lynch syndrome-related tumor, with one of the cancers being diagnosed at o50 years of age; or colorectal carcinoma diagnosed in two or more firstor second-degree relatives with Lynch syndromerelated tumors, regardless of age), and (3) colorectal tumor morphology associated with abnormal DNA mismatch repair including mucinous, signet-ring, or medullary morphology, increased tumor-infiltrating lymphocytes, and/or peri-tumoral lymphoid aggregates. 33 The second group was a prospective analysis that included all intestinal carcinomas, endometrial carcinomas, and skin sebaceous neoplasms accrued from April 2010 through November 2010 and tested for mismatch repair protein immunohistochemistry regardless of patient age or tumor morphology.
Mismatch Repair Protein Immunohistochemistry
Mismatch repair protein immunohistochemistry was performed using the standard streptavidin-biotin-peroxidase procedure. Primary monoclonal antibodies against MLH1 (clone G168-728; BD PharMingen, San Diego, CA, USA; 1:200), MSH2 (clone FE11; Oncogene Research Products, Cambridge, MA, USA; 1:100), MSH6 (clone 44; BD Transduction, San Jose, CA, USA; 1:200), and PMS2 (clone A16-4, BD Biosciences, San Jose, CA, USA; 1:10) were applied to 5-mm-thick formalin-fixed, paraffin-embedded whole tumor sections. The sections were deparaffinized in xylene, and rehydrated through graded alcohols to distilled water before undergoing antigen retrieval by heat treatment in either citrate solution pH 6.0 (MLH1, PMS2, and MSH2) or EDTA solution pH 9.0 (MSH6). An automated detection using the Ventana Benchmark XT Autostainer (Tucson, AZ, USA) was employed. Normal expression was defined as nuclear staining within tumor cells, using infiltrating lymphocytes as positive internal control. Negative protein expression was defined as complete absence of nuclear staining within tumor cells in the face of concurrent positive labeling in internal nonneoplastic tissues. Cases with immunoreactivity in o10% of tumor cells were repeated, and if the findings were confirmed then they were scored as equivocal. Cases lacking any expression in both tumor and nonneoplastic tissues underwent repeat immunohistochemical analysis using the same conditions. For PMS2, cases in the retrospective group lacking any expression in both tumor and nonneoplastic tissue were re-evaluated using an alternate PMS2 antibody (clone MRQ-28; Cell Marque, Rocklin, CA, USA; 1:10 with citrate antigen retrieval). All cases in the prospective group were analyzed with this alternate PMS2 antibody (clone MRQ-28; Cell Marque; 1:10 with citrate antigen retrieval). In addition, for the prospective group, two pathologists independently scored each case using only the MSH6 and PMS2 studies and documented their interpretation and overall impression of whether the two-antibody approach was sufficient for analysis of mismatch repair protein expression for each case.
MSI Polymerase Chain Reaction (PCR)
In the retrospective group, MSI analysis was performed on 117 cases of colorectal carcinomas reviewed before June 2007 using the Bethesda Panel of five microsatellite markers proposed by the National Cancer Institute (NCI): BAT25, BAT26, D2S123, D5S346, and D17S250. 34 Thereafter, all colorectal carcinomas, sebaceous neoplasms, and gynecologic tract tumors were analyzed using the ProMega MSI analysis system utilizing a panel of five mononucleotide microsatellite markers (BAT-25, BAT-26, NR-21, NR-24, and MONO-27) and two pentanucleotide repeats (Penta C and Penta D) incorporated into a multiplex fluorescence assay. 35 Briefly, the tests were performed on tumor and normal DNA extracted from paraffin-embedded tissue blocks using a DNease Tissue Kit (Qiagen, Valencia, CA, USA); manual microdissection was performed, when required, to exclude overabundance of nonlesional tissue. Paired DNA samples from neoplastic and nonneoplastic samples were genotyped and analyzed by capillary electrophoresis using an ABI 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). In accordance with NCI guidelines, MSI at Z2 loci was defined as MSI high (MSI-H), instability at a single locus was defined as MSI low (MSI-L), and no instability at any of the loci tested was defined as microsatellite stable (MSS).
Statistical Analysis
Fisher's exact test (two tailed), w 2 , or Student's t-tests were used to evaluate the correlation of mismatch repair protein immunohistochemistry and clinicopathological characteristics. The significance level was set at Po0.05.
Results
A total of 334 cases were in the retrospective group, including 260 colorectal carcinomas, 42 skin sebaceous neoplasms, 26 gynecologic tract carcinomas, and 6 neoplasms from various sites (stomach, ampulla, and central nervous system). A total of 98 cases were in the prospective group, including 63 colorectal carcinomas, 7 skin sebaceous neoplasms, 24 gynecologic carcinomas, and 4 small intestinal carcinomas. Overall, including both retrospective and prospective analyses, 59 of 323 (18%) colorectal carcinomas demonstrated loss of at least one mismatch repair protein ( Table 1 ). The median age of patients with colorectal carcinomas with abnormal mismatch repair protein expression was 44 years (range 26-80 years). Colorectal carcinomas with abnormal mismatch repair protein expression occurred more often in men (36/59, 61%) than women (23/59, 39%; P ¼ 0.04). The most common pattern of loss was concurrent MLH1 and PMS2 (34 cases, 11%) followed by concurrent loss of MSH2 and MSH6 (12 cases, 4%). Five (1.5%) colorectal carcinomas demonstrated isolated loss of PMS2 (Figure 1 ). Eight (2.5%) colorectal carcinomas displayed isolated loss of MSH6. Importantly, none of the colorectal carcinomas demonstrated isolated loss of MLH1 or isolated loss of MSH2. Of the 59 colorectal carcinomas demonstrating loss of at least one mismatch repair protein by immunohistochemistry, 49 (83%) were evaluated by MSI PCR ( (Table 3) . Of the four MSS tumors, three had abnormalities of MSH6: two cases with isolated loss of MSH6 and one case with concurrent loss of MSH2 and MSH6. All gynecologic tract carcinomas with intact expression of all four mismatch repair proteins evaluated by MSI PCR were MSS.
Of the 49 skin sebaceous tumors included in the retrospective and prospective analyses, most were either sebaceous adenomas or sebaceomas (26/49, 53%), with fewer numbers of sebaceous carcinomas (12 cases, 24%) and atypical sebaceous neoplasms (11 cases, 22%; Table 4 ). Overall, 24 cases (49%) demonstrated loss of at least one mismatch repair protein. The median age of patients with skin sebaceous neoplasms with abnormal mismatch repair protein expression was 62 years (range 49-91 years). In contrast to colorectal carcinoma, the most common pattern of loss was concurrent loss of MSH2 and MSH6 accounting for 17 (35%) cases. Fewer cases of concurrent loss of MLH1 and PMS2 were identified accounting for 6 (12%) cases. Isolated loss of MSH6 was seen in one (2%) case. (21) 23 (55) 14 (54) 0 (0) 5 (8) 1 (14) 5 (21) 0 (0) 102 (24) Loss of MLH1 and PMS2
31 (12) 6 (14) 7 (27) 0 (0) 3 (5) 0 (0) 3 (13) 0 (0) 50 ( 18 (43) 12 (46) 6 (100) 58 (92) 5 (71) 17 (71) 3 (75) 325 (75) a Antibodies yielding equivocal immunohistochemical staining listed in parentheses. A lack of PMS2 expression in both tumor and nonneoplastic tissue was observed in 13 colorectal carcinomas in our retrospective analysis; none of the gynecologic tract carcinomas, skin sebaceous neoplasms, or colorectal carcinomas in the prospective group exhibited this PMS2 staining pattern. The colorectal carcinomas exhibiting a lack of PMS2 immunoreactivity were re-evaluated using a different PMS2 antibody clone (MRQ-28). Using this alternate PMS2 antibody, eight cases exhibited intact PMS2 expression and five cases exhibited loss of PMS2 expression. We also encountered equivocal MSH6 staining (defined as o10% immunoreactivity in the neoplastic cells) in both the retrospective and prospective groups; however, equivocal MSH6 staining was only seen in the extraintestinal tumors (skin sebaceous neoplasms, two cases; gynecologic tract carcinomas, two cases; and small bowel carcinoma, one case) (Figure 3 ). All five cases with equivocal MSH6 staining exhibited intact expression of MSH2. In our prospective review using the two-antibody (PMS2 and MSH6) approach, equivocal MSH6 staining was identified in 4/98 (4%) cases and was the only deficiency noted with the two-antibody panel.
Discussion
Based on the heterodimer concept of mismatch repair proteins, we investigated a two-antibody immunohistochemical screening approach using PMS2 and MSH6 in colorectal carcinomas and extraintestinal Lynch syndrome-related neoplasms. In our analysis, PMS2 immunohistochemical analysis detected all cases with either MLH1 or PMS2 loss of expression. Similarly, the MSH6 immunohistochemical analysis detected all cases with either MSH2 or MSH6 loss of expression. Thus, no study cases exhibited isolated loss of expression of MLH1 or isolated loss of expression of MSH2. Our results confirm the utility of the two-antibody panel immunohistochemical screening approach in colorectal carcinoma as described by Shia et al, 31 and further indicate that the two-antibody approach is applicable to extraintestinal sites, particularly skin sebaceous neoplasms and gynecologic tract carcinomas.
Numerous reports have evaluated mismatch repair protein immunohistochemistry in skin sebaceous neoplasms, although most studies have employed only MLH1 and MSH2 in their immunohistochemical analysis. 14, 18, [36] [37] [38] To our knowledge, only one study has analyzed the expression of all four mismatch repair proteins in skin sebaceous neoplasms (Table 5) . 19 Orta et al 19 analyzed 27 patients with one or more sebaceous neoplasms and showed abnormal mismatch repair protein expression in 12 (44%) patients (Table 4) . Our analysis revealed a somewhat higher proportion (49%) of skin sebaceous neoplasms with abnormal mismatch repair protein expression, likely because patient selection for inclusion in our retrospective analysis was primarily based on clinical concern for MTS after evaluation of clinical characteristics 
Loss (Table 4) . Our results also demonstrate that abnormal mismatch repair protein expression is much more frequent in skin sebaceous tumors located on the trunk or extremities compared with head or neck and in men compared with women, similar to other reports in the literature. 14, 19 Gynecologic tract carcinomas have been more frequently studied with immunohistochemical antibodies for all four mismatch repair proteins than skin sebaceous tumors ( Our study was limited to only 10 extracolonic cases outside of the gynecologic tract and skin, and very little data are available in the literature regarding mismatch repair protein immunohistochemistry in these sites. 42 Of the 10 cases in our series, only one small bowel adenocarcinoma demonstrated equivocal MSH6 immunoreactivity, with the remainder demonstrating intact mismatch repair protein expression. Further analysis of these other potential Lynch syndrome-related tumors should be performed before any definite recommendations can be made. Difficulties in interpretation of mismatch repair protein immunohistochemistry did occur in our analysis and mostly relate to staining quality that may render interpretation of the stains difficult. 7 First, MSH6 staining is frequently patchy and weak in gynecologic tract carcinomas and skin sebaceous neoplasms, making confident interpretation difficult. Focal, weak immunoreactivity with MSH6 has been previously reported in colorectal carcinomas. 43 In addition, recently, partial intact MSH6 expression in colorectal carcinoma has been demonstrated to occur after neoadjuvant therapy or rarely in MLH1-and/or PMS2-deficient colorectal carcinomas. 44, 45 In our analysis, we identified a small number of gynecologic tract and skin sebaceous tumors with focal MSH6 immunoreactivity; none of these patients had received chemotherapy or had concurrent loss of immunohistochemical expression of any other mismatch repair proteins. Interestingly, in our analysis, focal MSH6 immunoreactivity was limited to extracolonic tumors with no cases of colorectal carcinoma demonstrating this pattern of immunoreactivity. Second, a minor subset of colorectal carcinomas in our retrospective analysis demonstrated lack of PMS2 immunoreactivity in both the tumor and normal tissues. With repeat analysis with a different PMS2 antibody clone (MRQ-28), we were able to reclassify PMS2 expression as intact or lost in these 13 colorectal carcinoma cases. Improved immunohistochemical procedures also likely had an impact on our analysis with PMS2 as most cases that lacked immunoreactivity in both normal and tumor tissues were cases from the early period of our retrospective analysis. Finally, the recognition of scattered lymphocyte reactivity of mismatch repair proteins within a tumor should be emphasized in assessing tumor cell reactivity. In our analysis, a small subset of cases with loss of mismatch repair protein expression were initially misinterpreted as tumor exhibiting intact mismatch repair protein expression by pathologists without knowledge of the potential pitfall of tumor-infiltrating lymphocytes. Such interpretative errors can be minimized by limiting the analysis of these studies to pathologists with sufficient exposure in assessing mismatch repair protein immunohistochemistry.
In clinical practice, we propose that the twoantibody panel including PMS2 and MSH6 can function as an initial screen in evaluation of Lynch syndrome-related tumors for abnormal mismatch repair protein immunohistochemistry. In all of the problem cases, particularly those cases with equivocal MSH6 results identified in our analysis, the inclusion of MLH1 and MSH2 analysis would not have changed the eventual interpretation of the immunohistochemistry results. Thus, an initial screen using two-antibody (PMS2 and MSH6) panel is equally as effective as the conventional fourantibody panel in screening for patients who harbor tumors with mismatch repair protein abnormalities and who should be further evaluated for the possibility of Lynch syndrome. However, after the initial two-antibody (PMS2 and MSH6) screen, any case exhibiting abnormal or equivocal mismatch repair protein expression should be evaluated with MLH1 and MSH2, as knowledge of the specific mismatch repair protein deficiency is extremely useful in helping to direct gene sequencing efforts to identify the disease-causing mutation in patients suspected of having Lynch syndrome. Importantly, immunohistochemical staining for mismatch repair proteins is complementary to MSI PCR studies. In general, immunohistochemistry is routinely available in general pathology laboratories and is less expensive compared with PCR detection of MSI. 46 In addition, mismatch repair immunohistochemistry can identify patients with low levels of MSI that may be missed by PCR analysis, particularly those patients with mutations in MSH6. [25] [26] Our analysis confirms the utility of MSH6 immunohistochemistry when screening for Lynch syndrome, as abnormalities of MSH6 expression accounted for most (78%) of the cases that were MSS or MSI-L by PCR analysis. However, MSI testing by PCR can potentially identify patients with defective DNA mismatch repair but intact immunohistochemical staining as a result of nontruncating missense alterations or defects in genes other than the four mismatch repair proteins routinely tested for by immunohistochemistry. Thus, in those patients with clinical concern for Lynch syndrome meeting requirements of the Bethesda criteria, both mismatch repair protein immunohistochemistry and MSI PCR should be performed.
In conclusion, a two-antibody panel including PMS2 and MSH6 is a cost-effective screening approach for identifying mismatch repair protein abnormalities in colorectal carcinoma, gynecologic tract carcinomas, and skin sebaceous neoplasms in patients suspected of having Lynch syndrome. Our analysis indicates that the two-antibody panel approach is equally effective as the conventional four-antibody panel in screening for patients who harbor tumors with mismatch repair protein abnormalities. One limitation of the two-antibody approach is the occurrence of equivocal MSH6 immunoreactivity that is more often observed in extracolonic Lynch syndrome-associated neoplasms. Finally, mismatch repair protein immunohistochemistry interpretative errors can be minimized by limiting the analysis of these studies to pathologists with sufficient exposure and knowledge of the potential interpretative pitfalls.
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